$MRNA
Moderna, Inc. Stock $mrna

$mrna Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-K Financial Statement

#000168285220000006 Filed on February 27, 2020

Income Statement

Concept	2019 Q4	2019 Q1	2019
Revenue	$14.06M	$16.03M	$60.00M
YoY Change	-60.32%	-44.82%	-55.58%
Cost Of Revenue			$0.00
YoY Change
Gross Profit			$60.00M
YoY Change			-55.58%
Gross Profit Margin			100.0%
Selling, General & Admin	$25.60M	$27.30M	$109.6M
YoY Change	-32.63%	67.48%	16.22%
% of Gross Profit			182.67%
Research & Development	$117.5M	$130.4M	$496.0M
YoY Change	-21.88%	44.7%	9.23%
% of Gross Profit			826.67%
Depreciation & Amortization	$9.000M	$7.300M	$31.00M
YoY Change	21.62%	40.38%	24.5%
% of Gross Profit			51.67%
Operating Expenses	$144.6M	$157.7M	$605.9M
YoY Change	-23.26%	48.13%	10.5%
Operating Profit	-$130.6M	-$141.6M	-$546.0M
YoY Change	-14.69%	82.99%	32.12%
Interest Expense	$6.200M	$9.400M	$32.20M
YoY Change	3.33%	80.77%	34.17%
% of Operating Profit
Other Income/Expense, Net	-$400.0K	-$1.931M	-$8.000M
YoY Change	-107.02%	955.19%	-535.97%
Pretax Income	-$123.3M	-$132.6M	-$515.0M
YoY Change	-12.74%	83.21%	35.36%
Income Tax	-$200.0K	-$24.00K	-$1.000M
% Of Pretax Income
Net Earnings	-$123.1M	-$132.6M	-$514.0M
YoY Change	-12.94%	83.18%	33.6%
Net Earnings / Revenue	-875.84%	-827.31%	-856.67%
Basic Earnings Per Share			-$1.55
Diluted Earnings Per Share	-$368.1K	-$403.3K	-$1.55
COMMON SHARES
Basic Shares Outstanding	333.3M shares	329.0M shares	331.0M shares
Diluted Shares Outstanding			331.0M shares

Balance Sheet

Concept	2019 Q4	2019 Q1	2019
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.103B	$1.109B	$1.103B
YoY Change	-27.49%		-27.5%
Cash & Equivalents	$236.0M	$502.9M	$235.9M
Short-Term Investments	$867.1M	$606.0M	$867.1M
Other Short-Term Assets	$9.000M	$8.000M	$9.500M
YoY Change	-18.18%		-13.64%
Inventory	$0.00
Prepaid Expenses	$8.475M	$7.895M
Receivables	$5.369M	$8.948M	$5.400M
Other Receivables	$11.00M	$17.00M	$10.90M
Total Short-Term Assets	$1.129B	$1.141B	$1.129B
YoY Change	-27.78%		-27.78%
LONG-TERM ASSETS
Property, Plant & Equipment	$288.0M	$209.5M	$287.9M
YoY Change	35.86%		35.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$160.0M	$438.0M	$160.0M
YoY Change	-7.51%		-7.51%
Other Assets	$1.931M	$2.438M	$12.70M
YoY Change	-26.97%		-10.56%
Total Long-Term Assets	$460.6M	$879.1M	$460.6M
YoY Change	15.4%		15.41%
TOTAL ASSETS
Total Short-Term Assets	$1.129B	$1.141B	$1.129B
Total Long-Term Assets	$460.6M	$879.1M	$460.6M
Total Assets	$1.589B	$2.020B	$1.589B
YoY Change	-19.0%		-18.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.090M	$38.51M	$7.100M
YoY Change	-77.28%		-77.24%
Accrued Expenses	$67.65M	$42.18M	$71.20M
YoY Change	-14.44%		-9.99%
Deferred Revenue	$63.31M	$81.78M
YoY Change	-41.95%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$143.1M	$159.2M	$143.1M
YoY Change	-35.77%		-35.77%
LONG-TERM LIABILITIES
Long-Term Debt	$39.00M	$33.00M	$38.70M
YoY Change	18.18%		15.52%
Other Long-Term Liabilities	$138.0K	$213.0K	$232.8M
YoY Change	-46.51%		32.57%
Total Long-Term Liabilities	$138.0K	$213.0K	$271.5M
YoY Change	-46.51%		29.84%
TOTAL LIABILITIES
Total Short-Term Liabilities	$143.1M	$159.2M	$143.1M
Total Long-Term Liabilities	$138.0K	$213.0K	$271.5M
Total Liabilities	$414.6M	$360.2M	$414.6M
YoY Change	-4.0%		-4.01%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.496B	-$982.4M
YoY Change	48.66%
Common Stock	$34.00K	$33.00K
YoY Change	3.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.175B	$1.442B	$1.175B
YoY Change
Total Liabilities & Shareholders Equity	$1.589B	$2.020B	$1.589B
YoY Change	-19.0%		-18.99%

Cashflow Statement

Concept	2019 Q4	2019 Q1	2019
OPERATING ACTIVITIES
Net Income	-$123.1M	-$132.6M	-$514.0M
YoY Change	-12.94%	83.18%	33.6%
Depreciation, Depletion And Amortization	$9.000M	$7.300M	$31.00M
YoY Change	21.62%	40.38%	24.5%
Cash From Operating Activities	-$99.10M	-$144.3M	-$459.0M
YoY Change	8.78%	29.52%	38.73%
INVESTING ACTIVITIES
Capital Expenditures	-$6.700M	$7.595M	$32.00M
YoY Change	-51.09%	-76.2%	-69.74%
Acquisitions
YoY Change
Other Investing Activities	$137.0M	-$4.200M	$16.60M
YoY Change	591.92%	-99.07%	-106.21%
Cash From Investing Activities	$130.4M	-$11.76M	-$15.00M
YoY Change	2003.23%	-97.57%	-95.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00	$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	30.80M	$293.0K	$52.00M
YoY Change	-94.65%	-99.95%	-95.76%
NET CHANGE
Cash From Operating Activities	-99.10M	-$144.3M	-$459.0M
Cash From Investing Activities	130.4M	-$11.76M	-$15.00M
Cash From Financing Activities	30.80M	$293.0K	$52.00M
Net Change In Cash	62.10M	-$155.7M	-$422.0M
YoY Change	-87.35%	245.35%	-180.71%
FREE CASH FLOW
Cash From Operating Activities	-$99.10M	-$144.3M	-$459.0M
Capital Expenditures	-$6.700M	$7.595M	$32.00M
Free Cash Flow	-$92.40M	-$151.9M	-$491.0M
YoY Change	19.38%	5.98%	12.45%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019	dei	Amendment Flag AmendmentFlag	false
CY2019	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2019	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019	mrna	Contract With Customer Asset Increase During Period ContractWithCustomerAssetIncreaseDuringPeriod	11890000	USD
CY2019	dei	Document Period End Date DocumentPeriodEndDate	2019-12-31
CY2019	dei	Document Type DocumentType	10-K
CY2019	dei	Entity Central Index Key EntityCentralIndexKey	0001682852
CY2020Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	368642548	shares
CY2019	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2019	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2019Q2	dei	Entity Public Float EntityPublicFloat	3380000000	USD
CY2019	dei	Entity Registrant Name EntityRegistrantName	Moderna, Inc.
CY2019	dei	Entity Shell Company EntityShellCompany	false
CY2019	dei	Entity Small Business EntitySmallBusiness	false
CY2019	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2019	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2018Q4	mrna	Accrued External Goods And Services Current AccruedExternalGoodsAndServicesCurrent	21578000	USD
CY2019Q4	mrna	Accrued External Goods And Services Current AccruedExternalGoodsAndServicesCurrent	36195000	USD
CY2018Q4	mrna	Accrued In Licenses Current AccruedInLicensesCurrent	22000000	USD
CY2019Q4	mrna	Accrued In Licenses Current AccruedInLicensesCurrent	0	USD
CY2018Q4	mrna	Accrued Property And Equipment Current AccruedPropertyAndEquipmentCurrent	12089000	USD
CY2019Q4	mrna	Accrued Property And Equipment Current AccruedPropertyAndEquipmentCurrent	4029000	USD
CY2019	mrna	Charges To Financing Lease Liabilities ChargesToFinancingLeaseLiabilities	971000	USD
CY2019	mrna	Contract With Customer Asset Decrease During Period ContractWithCustomerAssetDecreaseDuringPeriod	-14530000	USD
CY2019	mrna	Contract With Customer Liability Decrease During Period ContractWithCustomerLiabilityDecreaseDuringPeriod	-51987000	USD
CY2019	mrna	Contract With Customer Liability Increase During Period ContractWithCustomerLiabilityIncreaseDuringPeriod	10591000	USD
CY2018Q4	mrna	Deferred Tax Assets Capital Lease Obligation DeferredTaxAssetsCapitalLeaseObligation	9149000	USD
CY2018Q4	mrna	Deferred Tax Assets Capitalized Licenses Research And Development And Start Up Costs DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts	22143000	USD
CY2019Q4	mrna	Deferred Tax Assets Capitalized Licenses Research And Development And Start Up Costs DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts	19891000	USD
CY2019Q4	mrna	Deferred Tax Assets Financing Leases DeferredTaxAssetsFinancingLeases	10570000	USD
CY2019Q4	mrna	Deferred Tax Assets Operating Leases DeferredTaxAssetsOperatingLeases	26571000	USD
CY2019Q4	mrna	Deferred Tax Liabilities Finance Lease Right Of Use Asset DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset	2612000	USD
CY2019Q4	mrna	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	24944000	USD
CY2019	mrna	Finance Lease Cost FinanceLeaseCost	6866000	USD
CY2017	mrna	Increase Decrease In Deferred Rent Credit IncreaseDecreaseInDeferredRentCredit	2932000	USD
CY2018	mrna	Increase Decrease In Deferred Rent Credit IncreaseDecreaseInDeferredRentCredit	2420000	USD
CY2019	mrna	Increase Decrease In Deferred Rent Credit IncreaseDecreaseInDeferredRentCredit	0	USD
CY2018Q4	mrna	Lease Financing Obligation LeaseFinancingObligation	33489000	USD
CY2017	mrna	Lease Financing Obligations Incurred LeaseFinancingObligationsIncurred	1748000	USD
CY2018	mrna	Lease Financing Obligations Incurred LeaseFinancingObligationsIncurred	10089000	USD
CY2019	mrna	Lease Financing Obligations Incurred LeaseFinancingObligationsIncurred	0	USD
CY2017	mrna	Leasehold Improvements Incurred But Not Yet Reimbursed LeaseholdImprovementsIncurredButNotYetReimbursed	1748000	USD
CY2018	mrna	Leasehold Improvements Incurred But Not Yet Reimbursed LeaseholdImprovementsIncurredButNotYetReimbursed	10089000	USD
CY2019	mrna	Leasehold Improvements Incurred But Not Yet Reimbursed LeaseholdImprovementsIncurredButNotYetReimbursed	0	USD
CY2019	mrna	Leases Imputed Interest Rate LeasesImputedInterestRate	0.172
CY2019Q4	mrna	Operating And Finance Lease Liability OperatingAndFinanceLeaseLiability	135948000	USD
CY2019Q1	mrna	Operating And Finance Lease Liability OperatingAndFinanceLeaseLiability	108423000	USD
CY2019Q4	mrna	Operating And Finance Lease Liability Noncurrent OperatingAndFinanceLeaseLiabilityNoncurrent	132364000	USD
CY2019Q1	mrna	Operating And Finance Lease Liability Noncurrent OperatingAndFinanceLeaseLiabilityNoncurrent	101968000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	67652000	USD
CY2019Q4	mrna	Operating And Finance Lease Right Of Use Asset OperatingAndFinanceLeaseRightOfUseAsset	95958000	USD
CY2019Q1	mrna	Operating And Finance Lease Right Of Use Asset OperatingAndFinanceLeaseRightOfUseAsset	73187000	USD
CY2019	mrna	Operating Lease Liabilities OperatingLeaseLiabilities	12647000	USD
CY2017	mrna	Payments For Lease Financing Obligation PaymentsForLeaseFinancingObligation	1285000	USD
CY2018	mrna	Payments For Lease Financing Obligation PaymentsForLeaseFinancingObligation	2175000	USD
CY2019	mrna	Payments For Lease Financing Obligation PaymentsForLeaseFinancingObligation	0	USD
CY2019Q4	mrna	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	201495000	USD
CY2019Q4	mrna	Property Plantand Equipmentand Finance Lease Rightof Use Asset Accumulated Depreciationand Amortization PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetAccumulatedDepreciationandAmortization	94584000	USD
CY2019Q4	mrna	Property Plantand Equipmentand Finance Lease Rightof Use Assetbefore Accumulated Depreciationand Amortization PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization	296079000	USD
CY2017	mrna	Reimbursement Of Assets From Lease Financing Obligation ReimbursementOfAssetsFromLeaseFinancingObligation	2724000	USD
CY2018	mrna	Reimbursement Of Assets From Lease Financing Obligation ReimbursementOfAssetsFromLeaseFinancingObligation	11635000	USD
CY2019	mrna	Reimbursement Of Assets From Lease Financing Obligation ReimbursementOfAssetsFromLeaseFinancingObligation	0	USD
CY2019	mrna	Right Of Use Asset Operating Leases RightOfUseAssetOperatingLeases	5664000	USD
CY2019	mrna	Right Of Use Assets Reduced Through Lease Modifications And Reassessments RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments	2717000	USD
CY2019Q4	mrna	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue	4.86
CY2019	mrna	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue	4.47
CY2019	mrna	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue	8.67
CY2018Q4	mrna	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue	6.59
CY2019Q4	mrna	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue	7.35
CY2019Q4	mrna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue	9.86
CY2017	mrna	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	152000	USD
CY2018	mrna	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	2638000	USD
CY2019	mrna	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	0	USD
CY2018Q4	mrna	Tenant Incentives Receivables Current TenantIncentivesReceivablesCurrent	10089000	USD
CY2019Q4	mrna	Tenant Incentives Receivables Current TenantIncentivesReceivablesCurrent	4093000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	31210000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7090000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11686000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5032000	USD
CY2019Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8948000	USD
CY2018Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	899000	USD
CY2019Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	337000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	79073000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	64456000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1320000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1804000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2538155000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2669426000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	40055000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	72565000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	81122000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	152000	USD
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	40055000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	72565000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	81122000	USD
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	240375353	shares
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	51478444	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	46714164	shares
CY2018Q4	us-gaap	Assets Assets	1962149000	USD
CY2019Q4	us-gaap	Assets Assets	1589422000	USD
CY2019Q1	us-gaap	Assets Assets	2019962000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	1563006000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	1128804000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1037372000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1024106000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	173369000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	159148000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	172990000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	159987000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	1036053000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	1027111000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	864003000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	864958000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	863063000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	867124000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	863063000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	867124000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	172990000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	159987000	USD
CY2017	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	19959000	USD
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	12892000	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	4676000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	658364000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	235876000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	61560000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	147608000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	670491000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	247699000	USD
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	86048000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	522883000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-422792000	USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1600000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1600000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	775000000	shares
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1600000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	328798904	shares
CY2019	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	51987000	USD
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	336536985	shares
CY2017	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-252000	USD
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-26000	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2017	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-80000	USD
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	326000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	505000	USD
CY2019Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	161911000	USD
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	328798904	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	336536985	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	33000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	34000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-256670000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-384897000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-510897000	USD
CY2018Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	4612000	USD
CY2019Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	1972000	USD
CY2018Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	240924000	USD
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	199528000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	109056000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	63310000	USD
CY2019Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	81775000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	165352000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	138995000	USD
CY2017	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	172000	USD
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	352000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	505000	USD
CY2018Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	82800000	USD
CY2018Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	400000	USD
CY2018Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	25	security
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	0	security
CY2017	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-1200000	USD
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1200000	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	15228000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	36515000	USD
CY2018Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	10006000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	71209000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	53475000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	323501000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	507268000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	15228000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	36515000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	114932000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	268173000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2870000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	11000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	53617000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	77222000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	33138000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	43978000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	16443000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	7377000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	308273000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	470753000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	15228000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	8959000	USD
CY2017	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2100000	USD
CY2018	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2100000	USD
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	4200000	USD
CY2019	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.5
CY2019	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.06
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	20537000	USD
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	20500000	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	24900000	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	24862000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	31000000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	31021000	USD
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.18
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.16
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.43
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.32
CY2018Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.14
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.95
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.40
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.41
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.37
CY2019Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.37
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.55
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.204
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.285
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.330
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.250
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.000
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.000
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.011
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.002
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.002
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.013
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.000
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.016
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.005
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.002
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.085
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.063
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.079
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.048
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.015
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.025
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	23406000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	27428000	USD
CY2019Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	194800000	USD
CY2019	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y1M
CY2019	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	6557000	USD
CY2019	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	5585000	USD
CY2019Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	38689000	USD
CY2019Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	38689000	USD
CY2019Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	37718000	USD
CY2019Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	294448000	USD
CY2019Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	264156000	USD
CY2019Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	5738000	USD
CY2019Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	6387000	USD
CY2019Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	6219000	USD
CY2019Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	6054000	USD
CY2019Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	5894000	USD
CY2019Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	255759000	USD
CY2019	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	971000	USD
CY2019Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	9544000	USD
CY2019Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	9853000	USD
CY2019	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	309000	USD
CY2019Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.172
CY2019Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P33Y0M
CY2017	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2018	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-891000	USD
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-316000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-514716000	USD
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	64722000	USD
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	94252000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-6121000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-255996000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-384408000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	109620000	USD
CY2017	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2018	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2019	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-247784000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-380473000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-508595000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-8212000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-3935000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-80000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	326000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-695000	USD
CY2017	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	398000	USD
CY2018	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	294000	USD
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	416000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-12766000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	15017000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-23964000	USD
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1476000	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-195000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-6654000	USD
CY2017	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	1370000	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-637000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-562000	USD
CY2017	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	34369000	USD
CY2018	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	8787000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-3362000	USD
CY2017	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-162321000	USD
CY2018	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-65260000	USD
CY2019	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-44119000	USD
CY2017	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-145000	USD
CY2018	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	910000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-6169000	USD
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-579000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5289000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-9751000	USD
CY2017	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	2998000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2018Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	7909000	USD
CY2019Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	6835000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1589422000	USD
CY2019Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2019962000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	222803000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	143115000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	168000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1226842000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	51121000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	417364000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-373094000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14945000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-331484000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-330865000	USD
CY2017	us-gaap	Investment Income Interest InvestmentIncomeInterest	15235000	USD
CY2018	us-gaap	Investment Income Interest InvestmentIncomeInterest	27023000	USD
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	38530000	USD
CY2017	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-1086000	USD
CY2018	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	1866000	USD
CY2019	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	3742000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	173009000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	103439000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	12563000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	14708000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	14365000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	14120000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	13814000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	75750000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	431908000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	414612000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1962149000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-458968000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-255916000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-255900000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-384734000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-384700000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-514021000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-514000000	USD
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-269841000	USD
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-401857000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-514021000	USD
CY2019	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2017	us-gaap	Operating Expenses OperatingExpenses	475181000	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	106441000	USD
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	125866000	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	127575000	USD
CY2018Q4	us-gaap	Operating Expenses OperatingExpenses	188452000	USD
CY2018	us-gaap	Operating Expenses OperatingExpenses	548334000	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	157665000	USD
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	156792000	USD
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	146861000	USD
CY2019Q4	us-gaap	Operating Expenses OperatingExpenses	144611000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	605929000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-269356000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-77402000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-97015000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-85818000	USD
CY2018Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-153031000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-413266000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-141640000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-143709000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-129815000	USD
CY2019Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-130556000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-545720000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	17015000	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	97259000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3584000	USD
CY2019Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6455000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	93675000	USD
CY2019Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	64250000	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	16121000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	86414000	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	63334000	USD
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.097
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P12Y0M
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	211769000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	17235000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	20208000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	20937000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	20404000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	112958000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	20027000	USD
CY2017	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	18600000	USD
CY2018	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	19100000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2644000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1931000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-754000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-163000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	3124000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	412000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	31000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	323000	USD
CY2017	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-342000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-132000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	3447000	USD
CY2017	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	1148000	USD
CY2018Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3464000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5063000	USD
CY2019Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	9331000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	258000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	138000	USD
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1875000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1835000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7526000	USD
CY2017	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	0	USD
CY2018	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	0	USD
CY2019	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	0	USD
CY2017	us-gaap	Payments For Repurchase Of Redeemable Convertible Preferred Stock PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock	0	USD
CY2018	us-gaap	Payments For Repurchase Of Redeemable Convertible Preferred Stock PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock	8182000	USD
CY2019	us-gaap	Payments For Repurchase Of Redeemable Convertible Preferred Stock PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock	0	USD
CY2017	us-gaap	Payments Of Capital Distribution PaymentsOfCapitalDistribution	1483000	USD
CY2018	us-gaap	Payments Of Capital Distribution PaymentsOfCapitalDistribution	0	USD
CY2019	us-gaap	Payments Of Capital Distribution PaymentsOfCapitalDistribution	0	USD
CY2018	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	41322000	USD
CY2017	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	727203000	USD
CY2018	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	1227709000	USD
CY2019	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	1145226000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	58401000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	105766000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	31554000	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017	us-gaap	Preferred Stock Redemption Premium PreferredStockRedemptionPremium	0	USD
CY2018	us-gaap	Preferred Stock Redemption Premium PreferredStockRedemptionPremium	4127000	USD
CY2019	us-gaap	Preferred Stock Redemption Premium PreferredStockRedemptionPremium	0	USD
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	162000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	162000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	162000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	28399000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	19403000	USD
CY2019Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	28099000	USD
CY2018Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	10401000	USD
CY2019Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8475000	USD
CY2017	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2018	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	563026000	USD
CY2019	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2017	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	0	USD
CY2018	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	661111000	USD
CY2019	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	0	USD
CY2017	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	800438000	USD
CY2018	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	783373000	USD
CY2019	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	993181000	USD
CY2017	us-gaap	Proceeds From Repayment Of Loans By Employee Stock Ownership Plans ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans	0	USD
CY2018	us-gaap	Proceeds From Repayment Of Loans By Employee Stock Ownership Plans ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans	0	USD
CY2019	us-gaap	Proceeds From Repayment Of Loans By Employee Stock Ownership Plans ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans	2891000	USD
CY2017	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	402530000	USD
CY2018	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	177008000	USD
CY2019	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	168654000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	47200000	USD
CY2017	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	212000	USD
CY2018	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1427000	USD
CY2019	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	47259000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	276433000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	211977000	USD
CY2019Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	209494000	USD
CY2019Q4	us-gaap	Property Subject To Or Available For Operating Lease Number Of Units PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits	2	campus
CY2017	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2018	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2019	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2018	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	1833561000	USD
CY2017	us-gaap	Redeemable Preferred Stock Dividends RedeemablePreferredStockDividends	13925000	USD
CY2018	us-gaap	Redeemable Preferred Stock Dividends RedeemablePreferredStockDividends	12996000	USD
CY2019	us-gaap	Redeemable Preferred Stock Dividends RedeemablePreferredStockDividends	0	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	410459000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	454082000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	496309000	USD
CY2018Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	595000	USD
CY2019Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1032000	USD
CY2018Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	11532000	USD
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	10791000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1006627000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1500000000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1496454000	USD
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-982432000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	60209000	USD
CY2019Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	249500000	USD
CY2017	us-gaap	Revenues Revenues	205825000	USD
CY2018Q1	us-gaap	Revenues Revenues	29039000	USD
CY2018Q2	us-gaap	Revenues Revenues	28851000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-551365000	USD
CY2018Q3	us-gaap	Revenues Revenues	41757000	USD
CY2018Q4	us-gaap	Revenues Revenues	35421000	USD
CY2018	us-gaap	Revenues Revenues	135068000	USD
CY2019Q1	us-gaap	Revenues Revenues	16025000	USD
CY2019Q2	us-gaap	Revenues Revenues	13083000	USD
CY2019Q3	us-gaap	Revenues Revenues	17046000	USD
CY2019Q4	us-gaap	Revenues Revenues	14055000	USD
CY2019	us-gaap	Revenues Revenues	60209000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	34014000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	40055000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	72565000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	81122000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	64900000.0	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	22872221	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	10.13
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000	USD
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	5300000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	75600000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	5693179	shares
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	7354268	shares
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	11.35
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	220434000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	286310000	USD
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	50821132	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	45536915	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.16
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.82
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	70069000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	22664694	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	17.54
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.86
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	15.17
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	19.58
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	216241000	USD
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y11M
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y1M
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y7M
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	6945306	shares
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2891000	USD
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	563026000	USD
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	212000	USD
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1427000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	47259000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	-334810000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	1530241000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	1174810000	USD
CY2018	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	0	USD
CY2017Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	1176661000	USD
CY2018Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	1833561000	USD
CY2017Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	1209940000	USD
CY2018Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	1903887000	USD
CY2017Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	448686791	shares
CY2018Q2	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	509352795	shares
CY2018Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	509352795	shares
CY2017Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	448686791	shares
CY2018Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2019Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2018Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	508539515	shares
CY2017Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	448686791	shares
CY2018Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2019Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2018Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	508539515	shares
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	940000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	141000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	141000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	799000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	162500000	USD
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	4399000	USD
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	64497544	shares
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	81114183	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	330802136	shares
CY2019	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash, marketable securities, and accounts receivable. Our investment portfolio comprises money market funds, marketable debt securities, including U.S. Treasury securities, debt securities of U.S. government agencies and corporate entities and commercial paper. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in business operations. Bank accounts in the United States are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000. Our primary operating accounts significantly exceed the FDIC limits.</font></div></div>
CY2019	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have made estimates and judgments affecting the amounts reported in our consolidated financial statements and the accompanying notes. On an ongoing basis, we evaluate our estimates, including critical accounting policies or estimates related to revenue recognition, research and development expenses, income tax provisions, stock-based compensation, leases, and useful lives of long-lived assets. We base our estimates on historical experience and various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The actual results that we experience may differ materially from our estimates. Significant estimates relied upon in preparing these financial statements include, among others, those related to fair value of equity awards, revenue recognition, research and development expenses, leases, fair value of financial instruments, useful lives of property and equipment, income taxes, and our valuation allowance on our deferred tax assets.</font></div></div>

Files In Submission

Name	View Source	Status
0001682852-20-000006-index-headers.html	Edgar Link	pending
0001682852-20-000006-index.html	Edgar Link	pending
0001682852-20-000006.txt	Edgar Link	pending
0001682852-20-000006-xbrl.zip	Edgar Link	pending
a0001193125183449821_image43.jpg	Edgar Link	pending
a0001193125183449821_image44.jpg	Edgar Link	pending
a0001193125183449821_image45.jpg	Edgar Link	pending
a0001193125183449821_image46.jpg	Edgar Link	pending
a0001193125183449821_image49.jpg	Edgar Link	pending
a0001193125183449821_image50.jpg	Edgar Link	pending
a0001193125183449821_image51.jpg	Edgar Link	pending
a0001193125183449821_image53.jpg	Edgar Link	pending
a0001193125183449821_image54.jpg	Edgar Link	pending
a0001193125183449821_image55.jpg	Edgar Link	pending
a0001193125183449821_image57.jpg	Edgar Link	pending
a0001193125183449821_image60.jpg	Edgar Link	pending
a0001193125183449821_image73.jpg	Edgar Link	pending
a0001193125183449821_image74.jpg	Edgar Link	pending
a0001193125183449821_image76.jpg	Edgar Link	pending
a0001193125183449821_image78.jpg	Edgar Link	pending
a0001193125183449821_image79.jpg	Edgar Link	pending
a0001193125183449821_image81.jpg	Edgar Link	pending
a0001193125183449821_image82.jpg	Edgar Link	pending
a0001193125183449821_image85.jpg	Edgar Link	pending
a0001193125183449821_image86.jpg	Edgar Link	pending
a0001193125183449821_image88.jpg	Edgar Link	pending
a0001193125183449821_image89.jpg	Edgar Link	pending
a0001193125183449821_image90.jpg	Edgar Link	pending
a0001193125183449821_image92.jpg	Edgar Link	pending
a0001193125183449821_image93.jpg	Edgar Link	pending
a0001193125183449821_image95.jpg	Edgar Link	pending
a0001193125183449821_image97.jpg	Edgar Link	pending
a0001193125183449821_image98.jpg	Edgar Link	pending
a0001193125183449821_imagf01.jpg	Edgar Link	pending
a000119312518344982_001.jpg	Edgar Link	pending
a10kimage102a01.jpg	Edgar Link	pending
a10kimage103a01.jpg	Edgar Link	pending
a10kimage104a01.jpg	Edgar Link	pending
a10kimage105a01.jpg	Edgar Link	pending
a10kimage106a01.jpg	Edgar Link	pending
a10kimage107a01.jpg	Edgar Link	pending
a10kimage108a01.jpg	Edgar Link	pending
a10kimage109a01.jpg	Edgar Link	pending
a10kimage11.jpg	Edgar Link	pending
a10kimage110a01.jpg	Edgar Link	pending
a10kimage111a01.jpg	Edgar Link	pending
a10kimage12.jpg	Edgar Link	pending
a10kimage13.jpg	Edgar Link	pending
a10kimage14.jpg	Edgar Link	pending
a10kimage15.jpg	Edgar Link	pending
a10kimage16.jpg	Edgar Link	pending
a10kimage17.jpg	Edgar Link	pending
a10kimage18.jpg	Edgar Link	pending
a10kimage19.jpg	Edgar Link	pending
a10kimage20.jpg	Edgar Link	pending
a10kimage22.jpg	Edgar Link	pending
a10kimage23.jpg	Edgar Link	pending
a10kimage24.jpg	Edgar Link	pending
a10kimage25.jpg	Edgar Link	pending
a10kimage26.jpg	Edgar Link	pending
a10kimage27.jpg	Edgar Link	pending
a10kimage28.jpg	Edgar Link	pending
a10kimage99.jpg	Edgar Link	pending
a190203enginesimagea01.jpg	Edgar Link	pending
a190207pcv.jpg	Edgar Link	pending
a190207pcvii.jpg	Edgar Link	pending
a190215hmpvph1trialdesign.jpg	Edgar Link	pending
a190301pcv.jpg	Edgar Link	pending
a190309zikaourproductconcept.jpg	Edgar Link	pending
a190311krasvaccinefigure2019.jpg	Edgar Link	pending
a190312capture.jpg	Edgar Link	pending
a190312g67g21.jpg	Edgar Link	pending
a190312g67g212a01.jpg	Edgar Link	pending
bx05.jpg	Edgar Link	pending
bx06.jpg	Edgar Link	pending
bx07.jpg	Edgar Link	pending
bx09.jpg	Edgar Link	pending
bx10.jpg	Edgar Link	pending
bx12.jpg	Edgar Link	pending
bx13.jpg	Edgar Link	pending
bx14.jpg	Edgar Link	pending
bx17.jpg	Edgar Link	pending
bx19.gif	Edgar Link	pending
bx20.gif	Edgar Link	pending
bx21.gif	Edgar Link	pending
bx24.gif	Edgar Link	pending
bx25.gif	Edgar Link	pending
bx26.gif	Edgar Link	pending
bx28.gif	Edgar Link	pending
bx31.jpg	Edgar Link	pending
bx32.gif	Edgar Link	pending
chart-35f8657e18205095969.jpg	Edgar Link	pending
chart10.jpg	Edgar Link	pending
chart11.jpg	Edgar Link	pending
chart12.jpg	Edgar Link	pending
chart9.jpg	Edgar Link	pending
exhibit102512312019.htm	Edgar Link	pending
exhibit102612312019.htm	Edgar Link	pending
exhibit102612312019image1.jpg	Edgar Link	pending
exhibit21subsidiaries1.htm	Edgar Link	pending
exhibit23112312019.htm	Edgar Link	pending
exhibit31112312019.htm	Edgar Link	pending
exhibit31212312019.htm	Edgar Link	pending
exhibit32112312019.htm	Edgar Link	pending
exhibit32212312019.htm	Edgar Link	pending
exhibit4312312019.htm	Edgar Link	pending
figuresforword20180731cmv.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g18a17.jpg	Edgar Link	pending
image0001b.jpg	Edgar Link	pending
image1.jpg	Edgar Link	pending
ipchart.jpg	Edgar Link	pending
moderna10-k12312019.htm	Edgar Link	pending
modernacellmap022620a02.jpg	Edgar Link	pending
modernalogo.jpg	Edgar Link	pending
modularsynthesisproteinprod2.jpg	Edgar Link	pending
mrna-20191231.xml	Edgar Link	completed
mrna-20191231.xsd	Edgar Link	pending
mrna-20191231_cal.xml	Edgar Link	unprocessable
mrna-20191231_def.xml	Edgar Link	unprocessable
mrna-20191231_lab.xml	Edgar Link	unprocessable
mrna-20191231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
slide1pptx.jpg	Edgar Link	pending
slide2a01.jpg	Edgar Link	pending
slide4.jpg	Edgar Link	pending
slide4pptx.jpg	Edgar Link	pending
slide5pptx.jpg	Edgar Link	pending
translationlangcompariso.jpg	Edgar Link	pending
translationlangcomparisoa01.jpg	Edgar Link	pending
vaccinetransition022620002.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MRNA
Moderna, Inc. Stock $mrna

2019 Q4 Form 10-K Financial Statement

#000168285220000006 Filed on February 27, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRNA Moderna, Inc. Stock $mrna

2019 Q4 Form 10-K Financial Statement

#000168285220000006 Filed on February 27, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRNA
Moderna, Inc. Stock $mrna